PURPOSE OF THE STUDY.
To determine the preference for the new epinephrine autoinjector, Auvi-Q, or the EpiPen with regard to method of instruction, preference to carry, device size, and device shape.
Subjects were recruited from 12 office-setting research facilities throughout the United States. Participants (n = 693) were grouped into adults aged 18 to 65 years (241), caregivers who were parents/guardians aged 18 to 65 years of children aged 5 to 17 years (228), and children aged 11 to 17 years (224), with and without experience using an epinephrine autoinjector.
The Auvi-Q and EpiPen were evaluated by each participant in a randomly assigned order. Participants were given a scenario that involved anaphylaxis and were instructed to simulate the use of each device using trainers that did not have a needle or contain epinephrine. Subjects were expected to perform the device test by relying on the labeling and/or voice instruction or intuition to perform the simulated injection correctly. They could not communicate with proctors before or during the test and were not given patient information leaflets. After testing both devices, participants completed a survey to indicate their preference for Auvi-Q versus EpiPen.
Among all participants combined, Auvi-Q was preferred over EpiPen an all study end points (P < .001). For experienced and inexperienced participants in all 3 groups, Auvi-Q was preferred over EpiPen for method of instruction, preference to carry, and device size (all P < .001). The preference for Auvi-Q device shape was not significant among experienced children (P = .10), though it was significant for inexperienced children (P = .04) and for experienced and inexperienced adults and caregivers (P < .001).
This study found that a majority of patients in all groups, including adults, caregivers, and children, both with and without experience using an epinephrine autoinjector, preferred Auvi-Q over EpiPen.
Epinephrine is underutilized for anaphylaxis, and patients and caregivers of patients at risk for anaphylaxis do not always carry an epinephrine autoinjector and do not always use it correctly. Given the user preferences noted for this new device, it will be interesting to see in future studies whether the use of Auvi-Q could lead more patients and caregivers to carry epinephrine autoinjectors and to use them correctly when needed in an emergency.
- Copyright © 2013 by the American Academy of Pediatrics